Collegium Pharmaceutical Inc (COLL) Stock
Key stats
- Market cap
- $770.98M
- Price / Earnings ratio
- 19.9x
- EPS (TTM)
- $1.21
- Volume
- Loading
- 52-week high
- $50.79
- 52-week low
- $21.43
Source: third-party data provider, as of November 13, 2026
Compare with COLL
Recent news
Earnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to Decline
Earnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to Decline
COLL
COLL vs. DSNKY: Which Stock Is the Better Value Option?
COLL vs. DSNKY: Which Stock Is the Better Value Option?
COLL
Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?
Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?
COLL
New Strong Sell Stocks for October 7th
New Strong Sell Stocks for October 7th
COLLNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 60.42
- MACD 12/26/9
- 0.40
- EMA 9 of MACD
- 0.23
- MACD histogram
- 0.18
- SMA 50
- $22.99
- Price above SMA 50
- EMA 50
- $24.32
- Price above EMA 50
- SMA 200
- $32.36
- Price below SMA 200
- EMA 200
- $32.34
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $1.67 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Earnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to Decline
Earnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to Decline
COLLCOLL vs. DSNKY: Which Stock Is the Better Value Option?
COLL vs. DSNKY: Which Stock Is the Better Value Option?
COLLDoes Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?
Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?
COLLNew Strong Sell Stocks for October 7th
New Strong Sell Stocks for October 7th
COLL
Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
COLL
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates
COLL
Collegium Pharmaceutical Q2 Earnings Call Highlights
Collegium Pharmaceutical Q2 Earnings Call Highlights
COLL
DivcoWest Welcomes Collegium Pharmaceutical to One Lincoln
DivcoWest Welcomes Collegium Pharmaceutical to One Lincoln
COLL
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?
COLL
4 Defensive Stocks to Take Refuge in as Tech Sell-off Continues
4 Defensive Stocks to Take Refuge in as Tech Sell-off Continues
COLLNews tone: automated (AI) classification of the article's content, not a price prediction.
About Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Vikram Karnani | CEO, President & Director | 1975 |
| Ms. Colleen Tupper | Executive VP & CFO | 1976 |
| Mr. David Dieter | Executive VP, General Counsel & Corporate Secretary | 1964 |
| Dr. Thomas B. Smith FAAFP, M.D. | Executive VP & Chief Medical Officer | 1961 |
| Mr. Ian Karp M.B.A. | Head of Investor Relations | — |
| Ms. Jessica Cotrone | Senior Vice President of Corporate Communications & Corporate Affairs | — |
| Ms. Jane Gonnerman | Executive Vice President of Strategy & Corporate Development | — |
| Mr. Dean J. Patras | Chief People Officer | — |
| Mr. Scott Sudduth | EVP & Head of Technical Operations | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 60.42
- MACD 12/26/9
- 0.40
- EMA 9 of MACD
- 0.23
- MACD histogram
- 0.18
- SMA 50
- $22.99
- Price above SMA 50
- EMA 50
- $24.32
- Price above EMA 50
- SMA 200
- $32.36
- Price below SMA 200
- EMA 200
- $32.34
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $28.00
- Average
- $44.00
- High
- $50.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -12.1 | +6.7 | ||||||||||
| 2022 | -6.5 | +7.9 | +10.0 | -18.4 | -2.3 | +14.5 | -5.3 | +3.4 | -9.5 | +11.2 | +17.9 | +1.4 |
| 2023 | +19.1 | -9.5 | -10.5 | -1.8 | -4.0 | -3.8 | +6.2 | +2.9 | -5.9 | -4.4 | +17.6 | +20.2 |
| 2024 | +5.5 | +9.7 | +4.6 | -5.0 | -12.3 | -0.2 | +18.2 | -0.3 | +3.3 | -14.0 | -8.8 | -8.6 |
| 2025 | +12.2 | -6.9 | +5.0 | -8.1 | +7.7 | +0.9 | -1.5 | +29.0 | -10.6 | +2.4 | +29.3 | -1.2 |
| 2026 | +0.9 | -11.5 | -20.5 | +1.4 | -2.1 | +13.9 | -1.3 | -30.8 | -9.1 | +9.0 | +4.8 |
